Evaluation of anti-diabetic activity of Gliclazide formulation of Bangladesh on alloxan induced diabetes in mice

Abstract

Objective: Four marketed oral anti-diabetic gliclazide tablets in Bangladesh have been studied for their drug content, release profile and glucose lowering capacities. This sort of study is a good indicator for in vivo evaluation of the quality of an oral anti-diabetic preparation gliclazide. Method: Marketed preparations of gliclazide from different manufacturers were randomly chosen for this study. And the alloxan is used for the induction of diabetic in mice’s. Glucometer in used to peak blood from tail vein of mice’s for measuring glucose level. Result: The drug content was within the United State Pharmacopoeia (USP) specified limit (73-87%) in all cases. The blood glucose levels were investigated after 7 days in alloxaninduced diabetic (150mg/kg b.w) in mice’s (AIDMs); significant (P<0.05). After 14 days at 5hr of single dose (110 mg/kg body weight) treatment of the products; strongly significantly (p<0.01) reduced blood glucose level 54.75%, 61.93%, 56.5% and 61%respectively; which were consistent with anti-hyperglycemic effects of standard gliclazide (70%). Conclusion: All the products were found to be qualified in very significantly lowering blood glucose level. It may be inferred that of the gliclazide tablets of Bangladeshi manufacturers complies with the standard specifications for drug contents, dissolution and antihyperglycemic properties.